US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Biogen Inc.

BIIBNASDAQ

199.65

USD
+6.56
(+3.40%)
Market Closed
20.43P/E
12Forward P/E
0.79P/E to S&P500
29.239BMarket CAP
- -Div Yield
Google Trends
Recent Reddit Comments

Here are a few reasons why I don't buy QQQ:
AMZN

TSLA

NVDA

FB

COST

PEP

AVGO

CSCO

CMCSA

ADBE

INTC

TMUS

TXN

QCOM

AMGN

AMD

HON

INTU

PYPL

AMAT

ADP

BKNG

MDLZ

SBUX

ISRG

NFLX

CHTR

ADI

GILD

CSX

MU

REGN

VRTX

FISV

LRCX

ATVI

MAR

MRNA

PANW

ABNB

KDP

KHC

MELI

AEP

FTNT

MRVL

ORLY

KLAC

PAYX

EXC

ILMN

ASML

MNST

NXPI

SNPS

LULU

CTSH

CDNS

CRWD

CTAS

WDAY

DXCM

XEL

ADSK

WBA

AZN

IDXX

DLTR

MCHP

ROST

TEAM

JD

EA

VRSK

FAST

DDOG

ODFL

EBAY

BIIB

LCID

PCAR

ZS

BIDU

ALGN

CPRT

SGEN

ZM

SIRI

ANSS

VRSN

MTCH

CEG

SPLK

OKTA

NTES

SWKS

PDD

DOCU

1
Reply
Share
Report
Save
Follow

You missed the 50-page DD written by myself, an associate professor of internal medicine, and other PhDs, MDs, pharmacologists, and Investors.

The only thing silly here is your lack of nuance when criticizing an in-depth analysis. IMO, there is a 90% chance of FDA approval based on 440 data points, reviewing 6 papers on why drugs fail P3, etc.

Comparing Simufilam to BIIB highlights your lack of attention to detail. Lastly, you circle that shit by comparing 2 decades of research largely focused on the amyloid hypothesis.

1
Reply
Share
Report
Save
Follow

It does tell you how desperate AD patients are that they are still taking BIIB.

1
Reply
Share
Report
Save
Follow

U

W

BIIB

COIN

MARA

DASH*

GME

AMC

RBLX

TSLA

LCID

RIVN

SQQQ/QQQ

ARKK/SARK

TDOC*

SOFI

PTON

PINS

LYFT

UBER*

WISH

NKLA

PLUG

SPCE

1
Reply
Share
Report
Save
Follow

I hope you loaded up on puts yesterday when cramer said he likes Lilly $BIIB💪🏼💪🏼inverse that crackhead and gains are almost guaranteed

1
Reply
Share
Report
Save
Follow

The following stocks are only 4% from their peak. Weathered this correction strongly!

VLO -3.95% KO -3.85% BMY -3.71% XEL -3.67% WM -3.37% JNJ -3.34% PEP -3.33% MRK -2.96% PG -2.90% MO -2.59% HSY -2.52% K -2.44% CERN -0.36%

The following stocks are down over 50% from their peak. Clobbered!

MRNA -72.98% NFLX -72.84% PYPL -71.65% ETSY -69.72% GPS -66.99% PENN -61.69% ALGN -60.69% IPGP -59.37% GNRC -58.16% CDAY -56.95% MTCH -56.51% BIIB -55.73%

1
Reply
Share
Report
Save
Follow

Really, Wow not what I get.

Symbol,Impl Vol,IVRank,Mark,Net Chng ABNB,76.07%,88.9,153.700,-6.53 AKAM,45.87%,73.6,112.280,-3.55 AMD,76.12%,93.9,85.870,-4.12 ANET,68.13%,85.8,116.000,-5.34 BIGC,111.37%,65.9,17.880,-.80 BIIB,44.72%,13.4,207.530,-2.97 BKNG,60.49%,100.0,2211.110,-107.49 BP,51.99%,72.1,28.720,-.63 CAR,112.29%,45.5,267.670,-5.38 CHGG,99.89%,59.1,24.740,-.96 CROX,85.46%,92.3,66.750,-1.39 CVS,39.80%,100.0,96.130,-4.72 DASH,118.61%,99.8,81.540,-5.96 DBX,63.60%,67.6,21.750,-.71 DDOG,99.44%,94.7,121.500,-7.69 DOCN,132.76%,100.0,39.430,-4.57 EAT,79.91%,100.0,36.380,-2.51 EL,50.39%,100.0,264.060,-8.27 ETSY,103.88%,99.7,93.660,-8.69 EXPE,70.39%,99.3,175.330,-8.65 EXPI,113.63%,87.1,13.390,-.63 FSLY,132.96%,95.9,15.950,-1.20 FTNT,71.78%,97.3,289.500,-19.64 FUBO,160.15%,94.0,3.790,-.28 GDDY,54.04%,81.4,80.810,-6.52 IPI,109.87%,75.8,76.580,-6.48 IRBT,93.85%,89.0,50.650,+.29 LOGI,60.70%,68.2,65.300,-.70 LYFT,82.42%,85.9,32.720,-.96 MELI,85.58%,91.7,975.060,-66.37 MGM,58.46%,78.3,41.060,-1.07 MGNI,110.35%,73.5,9.650,-.60 MOS,80.75%,96.2,62.450,-2.90 MRNA,91.72%,72.1,135.000,-8.11 MTCH,82.66%,98.4,79.350,-2.45 NET,107.20%,96.9,86.260,-9.11 NTR,60.94%,91.1,98.250,-3.05 PENN,86.45%,89.9,36.700,-1.31 PFE,44.17%,88.3,48.680,-1.44 PRU,41.91%,71.6,108.510,-3.61 QSR,37.08%,89.9,57.150,-1.27 RACE,44.88%,71.8,209.740,-4.30 REGN,36.55%,76.6,659.210,-16.47 SBUX,47.33%,99.2,74.750,-1.94 SHAK,77.83%,96.9,57.830,-2.33 SHOP,104.01%,97.5,428.050,-16.46 SKLZ,152.62%,50.0,2.060,-.14 SQ,105.42%,93.6,99.800,-5.10 SWKS,64.64%,100.0,113.350,-4.35 TRIP,71.02%,66.6,25.670,-.69 TUP,87.47%,68.2,17.580,-.25 TWLO,103.28%,100.0,111.820,-7.10 UBER,79.30%,96.5,31.480,-1.34 VRTX,35.17%,30.5,273.220,+4.58 W,120.04%,97.2,77.020,-6.45 WING,74.37%,95.7,91.760,-6.02 YUM,38.07%,88.1,117.010,-2.51 ZBRA,52.01%,89.8,370.010,-13.32 ZG,94.13%,97.0,38.650,-.96 ZI,81.83%,88.1,47.400,-1.55

1
Reply
Share
Report
Save
Follow

Some implied ones for earnings next week - 1607 companies reporting : $SQ 15.8% $ZG 18.6% $DASH 18.5% $FUBO 22.4% $MELI 12.1% $DBX 9.2% $SHAK 15.5% $VRTX 5.0% $SHOP 14.6% $DDOG 15.6% $UBER 11.9% $TWLO 16.9% $ETSY 17.5% $NET 15.7% $FSLY 20.0% $SKLZ 26.8% $TRIP 11.5% $FTNT 14.0% $IRBT 18.7% $BKNG 8.8% $DOCN 24.9% $MGNI 20.7% $GDDY 10.6% $CROX 16.9% $PENN 11.1% $W 19.1% $AMD 10.9% $ABNB 10.7% $SBUX 6.7% $LYFT 12.8% $SWKS 9.4% $MTCH 10.7% $AKAM 7.7% $PRU 7.3% $MRNA 12.4% $CVS 5.2% $REGN 6.7% $YUM 5.0% $WING 13.2% $RACE 6.1% $EAT 14.2% $EXPI 21.5% $TUP 17.1% $CHGG 20.2% $CAR 18.7% $EXPE 10.6% $LOGI 11.3% $MGM 7.7% ?$ANET 11.2% $MOS 10.9% $ZI 16.3% $NTR 8.5% $IPI 20.9% $BIGC 21.5% $PFE 6.0% $BP 6.1% $BIIB 5.9% $QSR 6.8% ?$EL 9.7% $ZBRA 10.1%

1
Reply
Share
Report
Save
Follow

Just one, Biogen (BIIB)

I usually do a ton of DD before committing any kind of money but I like this stock.

1
Reply
Share
Report
Save
Follow

since when -1% needs to be in the news?

Biogen (BIIB) – Biogen fell 1% in premarket trading after the government announced that Medicare will limit coverage for Aduhelm, Biogen’s Alzheimer’s disease treatment. Coverage will only be provided for patients enrolled in clinical trials.

1
Reply
Share
Report
Save
Follow

Biogen, $BIIB, files final protocol with FDA for Alzheimer’s drug Aduhelm confirmatory trial.

Biden: let me test this shit [laughing]

1
Reply
Share
Report
Save
Follow

whats up with BIIB? it's right at the bottom of a price range that been there for years, is this a good opportunity? or is the threat that it falls out this range too much to risk?

1
Reply
Share
Report
Save
Follow

BIIB will buy out SAVA EOY. Mark my words

1
Reply
Share
Report
Save
Follow

Some implied moves for #earnings next week - 526 companies reporting:
$FB 6.7%
$GOOGL 5.7%
$AMZN 5.6%
$SNAP 17.8%
$PYPL 8.1%
$SBUX 5.1%
$AMD 9.3%
$SPOT 10.7%
$QCOM 8.2%
$ALGN 10.8%
$PENN 11.7%
$REGN 6.8%
$RCL 11.8%
$BIIB 5.1%
$MRK 3.4%
$EL 8.2%
$RL 7.1%
$CHKP 7.0%
$PINS 16.2%
$F 8.3%
$U 13.2%
$SWKS 7.8%
$SKX 10.4%
$FTNT 12.1%
$DECK 11.0%
$WWE 10.1%
$EA 6.4%
$GILD 5.4%
$MTCH 9.4%
$ABBV 3.9%
$RACE 5.6%
$BSX 6.4%
$CPRI 9.8%
$NXPI 7.0%
$UPS 6.5%
$XOM 4.3%
$SMG 9.4%
$SWK 7.7%

1
Reply
Share
Report
Save
Follow

Some implied moves for #earnings next week - 526 companies reporting:

​

$FB 6.7%
$GOOGL 5.7%
$AMZN 5.6%
$SNAP 17.8%
$PYPL 8.1%
$SBUX 5.1%
$AMD 9.3%
$SPOT 10.7%
$QCOM 8.2%
$ALGN 10.8%
$PENN 11.7%
$REGN 6.8%
$RCL 11.8%
$BIIB 5.1%
$MRK 3.4%
$EL 8.2%
$RL 7.1%
$CHKP 7.0%
$PINS 16.2%
$F 8.3%
$U 13.2%
$SWKS 7.8%
$SKX 10.4%
$FTNT 12.1%
$DECK 11.0%
$WWE 10.1%
$EA 6.4%
$GILD 5.4%
$MTCH 9.4%
$ABBV 3.9%
$RACE 5.6%
$BSX 6.4%
$CPRI 9.8%
$NXPI 7.0%
$UPS 6.5%
$XOM 4.3%
$SMG 9.4%
$SWK 7.7%

1
Reply
Share
Report
Save
Follow

I can provide you some in-dept DD later but if you're looking for fundamentally solid stocks that are trading at reasonable multiples and would do well in a rising interest rate environment I would consider things like INTC, Pharma names like (BMY, GILD, BIIB), safe tech/ 5G (T, VZ), recovery (CCL, BA, NCLH, LUV), a financial etf like the XLF or buying quality individual names like MS, GS, JPM, WFC, and so on.

Lastly, it's good to have some foreign market exposure so something like BABA, JD, TCEHY, or STNE is good.

This is not financial advice.

1
Reply
Share
Report
Save
Follow

Very fair! I was thinking tech feels more risky, and moved some funds from smaller cap tech stocks to larger. Still want the diversity, but felt smaller cap would face larger struggles if inflation continues to spiral and we see more rate hikes. Also with a new year I wanted to buy more ibonds. I also sold an asset management company, because my theory would have played out already if it was going to come to fruition. That fin company was 1.5% of my portfolio, and I sold at a -12% loss… I don’t sell all my losers I’m still bag holding BIIB at -15%, and DIS.

1
Reply
Share
Report
Save
Follow

Yeah. First, it makes the drug appear to have more effect, 1.1 pts in this case. Because they stopped sharing baselines after receiving this criticism, we don’t know what’s happening in later days disclosures. This was how the BIIB drug arguably got most of its effects- more apoe4 carriers dropped and they decline faster than others. Anyway, this skews data and being not transparent about what is going on makes it worse.

Second issue is that you want the trial to have largely similar patients to be a good trial design. This is exactly not that.

1
Reply
Share
Report
Save
Follow

Shorting biotech is pretty free money esp in AD. Puts on biib or crtx was just free cash, both bad companies theres a lot of them in biotech

1
Reply
Share
Report
Save
Follow

I suspected the price action reflects investors sentiment associated with $BIIB and their products more so than their views of $SAVA itself. The underlying premise of $BIIB drug is to remove aggregated plaques with targeting antibodies and there is not effect. Having plaques that can autocatalyze while augmenting the protein folding response will not address the underlying issue. I also acknowledge that he field is still unsure if it’s the presence of large plaques vs generation of the plaques and resulting cell death is the causative factor. Nevertheless, the price action may not just be a reflection of this report

1
Reply
Share
Report
Save
Follow

Biib

1
Reply
Share
Report
Save
Follow

Here's another from r/investing

​

|ticker| | |
|:-|:-|:-|
|IPO|0.897867|3|
|LMAO|0.772333|3|
|BRK.B|0.7339|3|
|RE|0.6208|4|
|TV|0.530017|6|
|DD|0.50746|5|
|FB|0.504667|9|
|MVIS|0.4885|3|
|AI|0.46698|5|
|MS|0.462433|3|
|GL|0.446067|3|
|QQQ|0.439367|9|
|BIIB|0.414933|3|
|PLTR|0.4074|8|
|NYC|0.39298|5|
|IQ|0.385967|3|
|TQQQ|0.3746|4|
|BB|0.3696|4|
|RRR|0.367946|13|
|TTM|0.3373|3|
|AAPL|0.314617|18|
|NET|0.298|4|
|USA|0.293213|15|
|SE|0.289267|6|
|AMD|0.275089|27|
|AND|0.27355|6|
|WISH|0.2671|3|
|OR|0.2604|3|
|CPI|0.25644|10|
|IMO|0.246925|8|
|TSLA|0.240779|14|
|NVDA|0.237017|6|
|AMZN|0.175875|4|
|CD|0.175325|8|
|AMC|0.1741|3|
|OP|0.172806|32|
|TD|0.16258|5|
|MSFT|0.156154|13|
|REIT|0.1469|3|
|IBKR|0.120475|4|
|VERY|0.079367|3|
|DM|0.0706|4|
|GME|0.042729|34|
|SQ|0.0369|5|
|IS|0.0183|5|
|HIMX|0.012925|4|
|JPM|-0.06338|8|
|BABA|-0.08628|8|
|ETC|-0.1001|3|
|TA|-0.1199|5|
|UK|-0.13508|4|
|IRS|-0.1822|4|
|TIL|-0.1891|4|
|ALL|-0.21113|4|
|NVAX|-0.4499|3|
^Table ^formatting ^brought ^to ^you ^by ^[ExcelToReddit](https://xl2reddit.github.io/)

1
Reply
Share
Report
Save
Follow

BIIB is about as unethical as any entity can be. To have a drug you know doesn’t work but in fact causes damage, and then to go and charge that amount for it? Lol, they didn’t even work over time (I walk right passed and live down the street from) at corporate during what should have been a crises.

There are a few actually promising AD companies/drugs in the works. Actually my largest single position is one because I know it well. T is good, I went in heavy there in Q4, 2021.

1
Reply
Share
Report
Save
Follow

> BIIB will be volatile until there’s more clarity on whether a market exists for its Alzheimer drug

I was under the impression that Aduhelm essentially doesn't work; regardless of whether it was cheap or not, it may be going after the wrong therapeutic target altogether. My feeling was that if it was cheap, neurologists might prescribe it in a throw-everything-at-the-wall-and-see-what-sticks approach.

That said, we don't know a lot about Alzheimers, and there may be molecular subtypes of disease where the drug might work (my research background is in cancer and not neurological disease, so I'm not willing to speculate much here).

1
Reply
Share
Report
Save
Follow

I tend to be a buy and hold investor, but I will be looking at valuations closely this year and opportunities to rotate into higher moat value stocks. I look at specific names as much as sector. Corporate profits are still quite healthy, but valuations are very high and I’m anticipating a lackluster year for the market.

I think extraordinarily low interest rates pushed more investors into stocks to get any kind of yield, and with interest rates going up, there is pent up demand to return some of that money into lower risk investments. That will be a modest headwind.

T and BIIB have taken a beating. I think T is undervalued at this point. BIIB will be volatile until there’s more clarity on whether a market exists for its Alzheimer drug, but its price already reflects a negative outlook, so I think it has potential to pop on any positive developments. I think medical devices in particular are worth keeping an eye on. The revenue hit from the pause in elective medical procedures has largely been factored into prices there. If we get a break from Covid, there could be some good buys there.

Not in any way a financial analyst. I only play one on tv.

1
Reply
Share
Report
Save
Follow

New science paper says multiple sclerosis is caused by Epstein-Barr virus. A vaccine could prevent multiple sclerosis. https://www.science.org/doi/10.1126/science.abj8222

Calls on MRNA, short BIIB

1
Reply
Share
Report
Save
Follow

I am unemployed atm. Here are my options for tmr:

  1. Maybe i should stop playing with money?
  2. Continue pretending money is fake and keep punting (My deep out of money puts on tsla are still not giving me value) so keep on adding puts and get trapped once again
  3. YOLO -> Use a randomizer to pick names I want to long and short? (For tmr the randomizer says LONG PYPL, ABNB, ZM and SHORT BIIB, LCID, AAPL)

I quite like option 3

1
Reply
Share
Report
Save
Follow

Did anyone buy the BIIB dip yesterday

1
Reply
Share
Report
Save
Follow

BIOGEN (BIIB) went down a lot because their Alzheimer’s drug has been removed from Medicare’s approved medicines. It’s extremely undervalued at this point

1
Reply
Share
Report
Save
Follow

>*BIOGEN ENCOURAGES PATIENTS TO MAKE VOICES HEARD: CEO $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2022-01-13 ^08:12:31 ^EST-0500

1
Reply
Share
Report
Save
Follow

I agree with OP that the stock is undervalued and mispriced, with an asymmetric risk to upside.

There is a quote from Neil deGrasse Tyson that science doesn't care whether you believe it or not. SAVA doesn't require retails or anyone else to purchase the stock to set the share price. The stock is set by the value of a functioning Alzheimer treatment.

I look at the 2021-2022 $BIIB chart and see an extra $27B in Biogen market cap for their FDA-approved Alzheimer drug that was then taken away after it fizzled with Europe declining approval, low sales, its brain bleed side effects, and then the extra whammy last night of Medicare draft yesterday declining covering unless in a trial. So I rate that the value of a suboptimal Alzheimer drug from Biogen was $27B.

SAVA is around $2B now, and the initial data from phase 2 is their candidate drug has more impressive benefits than Biogen's, with no serious side effects. My SAVA target is thus conservative at $500, but I respect OP and others who have their own higher targets. SAVA is my favorite stock for this year, my largest individual stock holding, and I backed up the truck even more today.

The next few weeks I feel are going to be popcorn-worthy. Good luck to anyone in the play.

1
Reply
Share
Report
Save
Follow

I just put most of my money into $BIIB puts. I'll probably be in a Wendy's uniform also.

1
Reply
Share
Report
Save
Follow

The only stocks that fall under the description of "down 50% from their 52 week highs right now" are BIDU, BIIB, DOCU, MRNA, PDD, and PTON.

I'm not seeing anywhere near 40%.

1
Reply
Share
Report
Save
Follow

Buying BIIB weekly calls

1
Reply
Share
Report
Save
Follow

BIIB deserves to drop hard. That drug should have never been approved.

1
Reply
Share
Report
Save
Follow

Big news for Biogen: BIIB

https://www.washingtonpost.com/health/2022/01/11/alzheimers-drug-aduhelm-medicare-coverage

1
Reply
Share
Report
Save
Follow

Anyone know why $BIIB, Biogen, is down in AH?

1
Reply
Share
Report
Save
Follow

BIIB what you doin?

1
Reply
Share
Report
Save
Follow

Will Medicare cover Aduhelm?

I feel like buying some BIIB calls

1
Reply
Share
Report
Save
Follow

Will Medicare cover Aduhelm?

I feel like buying some BIIB calls

1
Reply
Share
Report
Save
Follow

I read the legal agreements, and my interpretation is they are obligated to pay the bonuses so long as after doing so they have 24 months of burn.

I don't agree with the LLY or BIIB approvals by the way.

There are sometimes phase 2 results that do show efficacy - but they are placebo controlled! The company made a choice to not do placebo phase 2 for cog data past 28 days, and instead did OLE. OLE is pretty good for getting more safety data, and yes, this drug appears safe.

But they couldve gotten a lot more placebo data for not a lot more money. Odd that they chose not to. I wonder why?

1
Reply
Share
Report
Save
Follow

The ADOS-Cog score is what matters! Not causing brain bleeding is a nice bonus compared to BIIB.

1
Reply
Share
Report
Save
Follow

BIIB.

1
Reply
Share
Report
Save
Follow

Yeah I agree, I’ve been looking at its competitors (BIIB) and they have the same price action but when it gaps up there is no rhyme or reason. It just trades sideways then boom back up 400%.

1
Reply
Share
Report
Save
Follow

What a douche bag. I have read the QMC report, and it's full of bullshit like you.

Don't you remember being a child?? Making mistakes, questioning your actions, unsure of yourself? She was a child who saw her family fall apart and temporarily recanted.

Further, her actions from decades ago are reasons to discredit her??? Is there any point in discussing chain of custody, CRAs, that those same sites ran trials for BIIB and LLY...?

I am not wasting any time. In fact, I hope you have a short position.

You shorts are amoral and morons.

1
Reply
Share
Report
Save
Follow

Bought last week. This is my most risky play, but I really do like their product and I think they are the only one well positioned to grab a ton more market share.

BIIB screwed me like the day after I bought it. Long term bag holder on Verizon too.

1
Reply
Share
Report
Save
Follow

Made 40% this morning on BIIB puts. Now for a bowl break, then see if anything else in my port wants to move or just keep this sideways shit.

1
Reply
Share
Report
Save
Follow

>U.S.-LISTED SHARES OF BIOGEN INC DOWN 5.8% PREMARKET AFTER SAMSUNG BIOLOGICS DENIES REPORT OF SAMSUNG GROUP IN TALKS TO BUY CO $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-12-30 ^06:42:30 ^EST-0500

1
Reply
Share
Report
Save
Follow

GL to anyone that tried to chase BIIB (Biogen) today.

Samsung denying the merger report.

1
Reply
Share
Report
Save
Follow

BIIB gonna tank tomorrow, Samsung confirmed that buying BIIB isn't true uh oh

1
Reply
Share
Report
Save
Follow

Holy cow that drop on BIIB gonna be something tomorrow

1
Reply
Share
Report
Save
Follow

Woah that Biib plunge gonna be something tomorrow

1
Reply
Share
Report
Save
Follow

I’m getting paid tomorrow. Bought puts on BIIB after the buyout rumor by Samsung which they just denied. Can’t believe “investors” actually fell for it. Fucking retards….

1
Reply
Share
Report
Save
Follow

They should be moving to biib you know what we could in 2 days... diabolical shit but nope no hype gme zucked u all dry

1
Reply
Share
Report
Save
Follow

BIIB

1
Reply
Share
Report
Save
Follow

Samsung looking to buy Biogen who's got BIIB calls?

1
Reply
Share
Report
Save
Follow

Imagine biib calls

1
Reply
Share
Report
Save
Follow

Shit like BIIB really makes you realize you could change your life in mere moments if you’re at the right place at the right time. Hopefully I’ll be so lucky one day. >!Probably not though!<

1
Reply
Share
Report
Save
Follow

Samsung buy BIIB

1
Reply
Share
Report
Save
Follow

Samsung buy BIogen BIIB 🚀🚀🚀

1
Reply
Share
Report
Save
Follow

Samsung buy BIIB !

1
Reply
Share
Report
Save
Follow

Samsung buy BIIB so…. BIIB 🚀🚀🚀

1
Reply
Share
Report
Save
Follow

BIIB go top ✈️

1
Reply
Share
Report
Save
Follow

Try BIIB 🚀

1
Reply
Share
Report
Save
Follow

Try BIIB !

1
Reply
Share
Report
Save
Follow

Today BIIB day !

1
Reply
Share
Report
Save
Follow

I didnt buy or inverse. Making a nice pop on BIIB buyout talks today tho

1
Reply
Share
Report
Save
Follow

Yolo time for late biib calls

1
Reply
Share
Report
Save
Follow

BIIB was the play today

1
Reply
Share
Report
Save
Follow

No one told me about BIIB :(

1
Reply
Share
Report
Save
Follow

Shorts on BIIB got clapped

1
Reply
Share
Report
Save
Follow

BIIB buy the rumor

1
Reply
Share
Report
Save
Follow

BIIB taking off, Samsung buyout rumours

1
Reply
Share
Report
Save
Follow

Biib solely from acquisition rumors or is it a squeeze?

1
Reply
Share
Report
Save
Follow

Damn BIIB let’s go

1
Reply
Share
Report
Save
Follow

>Samsung Group in negotiations to buy Biogen - kedglobal kedglobal.com/newsView/ked20… $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-12-29 ^14:10:06 ^EST-0500

1
Reply
Share
Report
Save
Follow

Let me guess Pot stocks maybe 🤔 BIIB

1
Reply
Share
Report
Save
Follow

>JAPAN PANEL SAYS IT CAN'T BACK BIOGEN'S ADUHELM AT THIS POINT $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-12-22 ^06:07:48 ^EST-0500

1
Reply
Share
Report
Save
Follow

Cash 20,27%

CVS 16,13%

MSFT 10,47%

GOOG 9,23%

JPM 8,49%

BK 5,37%

WFC 4,36%

UNH 3,90%

INTC 3,25%

C 3,23%

JNJ 2,99%

BAC 2,40%

MU 2,32%

CMCSA 2,19%

MRK 2,18%

BMY 1,67%

BIIB 1,50%

OGN 0,05%

1
Reply
Share
Report
Save
Follow

Too late, FDA says fuck you BIIB

1
Reply
Share
Report
Save
Follow

>*Biogen Cuts Aduhelm List Price in Half &gt;*Price Cut Will Reduce Aduhelm's Average Annual Price to $28,200 Per Patient &gt;*New Aduhelm Price Is Nearly 50% Reduction From Aduhelm's $56,000 Launch Price $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-12-20 ^07:03:28 ^EST-0500

1
Reply
Share
Report
Save
Follow

>Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-12-20 ^07:01:21 ^EST-0500

1
Reply
Share
Report
Save
Follow

MRK, GSK, GILD would be my picks. BIIB if you’re feeling a bit riskier.

1
Reply
Share
Report
Save
Follow

>*BIOGEN'S ALZHEIMER DRUG GETS NEGATIVE RECOMMENDATION IN EU $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-12-17 ^06:06:24 ^EST-0500

1
Reply
Share
Report
Save
Follow

>*Biogen,TheraPanacea Announce New Collaboration $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-12-14 ^07:01:03 ^EST-0500

1
Reply
Share
Report
Save
Follow

10 stocks, 2 ETFs and Bitcoin

BABA, INTC, BIIB, FB, MOMO, STNE, KWEB, GDX, VIPS, DOYU, CCL, IRBT

1
Reply
Share
Report
Save
Follow

current portfolio—— BIIB, CR, FANG, CVX, INTC, LRCX, NXPI, REGN, SoFi, and SCYX

around equal weight

thoughts?

1
Reply
Share
Report
Save
Follow

>*U.S. INSURERS BALK AT PAYING FOR BIOGEN ALZHEIMER'S DRUG $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-11-18 ^10:13:03 ^EST-0500

2
Reply
Share
Report
Save
Follow

I like $SAVA here. There’s an apparent $80 floor, Simuflam has no side effects, and the FDA has approved a petition to allow $SAVA to conduct phase 4 trials

Huge short interest and earnings call tonight, perhaps announcing it. Also if you are aware of the whole $BIIB Aduhelm situation it works for $SAVA. Simuflam is safe so it’s gonna get approved-ski

nov 19th 110c

1
Reply
Share
Report
Save
Follow

>BIOGEN INC - THERE IS NO CONFIRMATION THE DEATH IS RELATED TO ADUHLEM AS IT IS STILL UNDER INVESTIGATION $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-11-09 ^13:40:30 ^EST-0500

0
Reply
Share
Report
Save
Follow

>RBC finds AERS data showing seizures, one death in patient on Biogen's Aduhelm $BIIB

^*Walter ^Bloomberg ^@DeItaone ^at ^2021-11-08 ^15:38:09 ^EST-0500

2
Reply
Share
Report
Save
Follow

$NIO 41c weeklies. $NFLX delayed reaction off of gaming news to ATH? $BIIB off of an FDA alzheimer medication $PFE on Vaccinating kids CDC vote $FUBO for a $35 PT $BENE has eyes due to EOD random spike today $BBBY for its final leg up tomorrow into possible GAP fill $CLOV lotto end of November Calls in preparation for Meme season

2
Reply
Share
Report
Save
Follow

>DNEs = lost profits. Why would anyone use these?

Because the stock moves significantly after the 4pm threshold. Look at TSLA, NKLA, BIIB last year (search this thread or /r/thetagang). Your once valuable option is totally out of the money. If you do not submit a DNE, you lost profits.

-1
Reply
Share
Report
Save
Follow

That’s the latest casualty but even BIIB, who got FDA approval, are now lower than they were prior to the approval.

Granted the drug was whack and never should have received approval, it’s still amazing.

2
Reply
Share
Report
Save
Follow

Blossoming thetafag here, is it just me or are biib end of week weekly prices kind of ridiculous

0
Reply
Share
Report
Save
Follow

I'm doing pretty solid.

I scored big on $BIIB earlier in the year when they jumped on their Alzheimer's drug approval and I sold before they slipped back down.

20% of my taxable portfolio is in leveraged ETF's like TQQQ and UPRO. I understand that the general consensus is that these are not good for long term holds, and I understand decay, but my current strategy is to DCA them for a few years and see how they ride. They make up less than 5% of my total net worth so I'm not concerned about getting wiped.

The rest is in VTI and VGT and a handful of individual stock picks.

This is just my taxable brokerage account obviously.

My retirement accounts are simply in diversified index funds and I don't mess with them.

1
Reply
Share
Report
Save
Follow

Thinking about

01/21/22 SNAP 85c

11/19/21 CMG 2000c

11/19/21 INTC 54p

11/19/21 BIIB 250p or 230p (maybe)

10/22/21 TSLA 800p

1
Reply
Share
Report
Save
Follow
Recent Tweets
$BIIB Signal Update As of today, BIIB is up +3.35% from buy price 190.40 on same day and on track to achieve target price 197.74. For more detail check our signals for free at https://t.co/EOn2oBnKve #trading #StockMarket #stocks #daytrading https://t.co/mEqzHvcXRS
0
0
0
$BIIB 🚀All that you need to know, Shorts haven't covered a single share.🚀 https://t.co/0PEtodswIp
0
0
0
$BIIB CADTH does not accept new evidence demonstrating SPINRAZA™'s effectiveness and safety for treating SMA – a progressive, life-altering neurodegenerative disease (Biogen Inc) (More at https://t.co/UJbplijGmd)
0
0
2
💥 $IDVV announced an agreement valued at over one million dollars to develop a solar powered clean energy project along with cryptocurrency mining in Mexico. https://t.co/raEtUFkqdN $MYL $VRX $VRTX $BIIB $BMY $JNJ $CELG $AKRX $REGN $JNJ $PFE $GSK $LLY $ABT $SNY $NVO $NVS $WBA
0
0
2
I thought she’d be a natural for the $BIIB CEO, or a senior post at $SRPT? https://t.co/b5mfJi9NzC
0
0
2
$BIIB 75% Win rate on 13 trades in 1 month. Profit Factor of 2.46, rating is Bearish. ▶ Stock Trading Ideas by https://t.co/6vnULU2sSf https://t.co/nTjjz3pkPM
0
0
0
I was working through $BIIB monthly, weekly and Daily chart and all I can say is, it might go to shit...
0
0
1
RA bottom fishing with a boatload of $BIIB
0
0
3
RA 1Q 13F BUYS (2/2): NEW: $BIIB +737,024 (3.34% of book) $GH +476,380 (0.69%) $MORF +278,874 (0.24%) $CCXI +1,115,964 (0.63%) $ENTA +964,212 (1.50%) $ANTX +3,666,663 (1.21%) $VERA +1,966,084 (1.01%) $ALVR +1,440,525 (0.21%) $NTRA +1,310,289 (1.16%) $ACRS +1,817,808 (0.68%)
1
0
5
$BIIB Below Avg Volume Daily appearances since 2010: 155 Close 5 days later ±: Avg: -0.95 SD: 12.52 Worst: -80.31 Best: 50.59 10 days later: Avg: -1.77 SD: 16.92 Worst: -84.75 Best: 65.00 30 days later: Avg: -1.29 SD: 34.74 Worst: -88.61 Best: 147.11
0
0
0
TrollEvent $BIIB Observation: Not Prediction. All Data As Is: No Claims, Warranties; Data Time Delayed. Best viewed as irrelevant pretty pictures: Entertainment value only. Evaluate BIIB with own Methods. https://t.co/xw7ZooemhM
0
0
0
Can’t cure Alzheimer yet.. $BIIB
0
0
0
If Biden is unhappy with corporate profit margins, he should set fix them. Just needs to nationalize the private sector first.
64
54
697
Saw my buddy, former CFO of $BIIB this morning. Had a interesting conversation about Biotech, will be something to watch especially if a blue sweep remains after mid terms
1
0
6